BSECompany Update13 Aug 2026 · 13 Aug 2026, 11:56 am
Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting
Alivus Life Sciences Ltd · 543322
✦ AI SummaryMgmt Change
Alivus Life Sciences Ltd has announced an investors/analyst meeting on August 18-19, 2026, with various investment firms, including Green Lantern Capital, SIMPL, Burman Capital, and Karma Capital.
Analysis Scores
Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk0/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment0/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Attachments (1)
📄pdf
Download →
c8e7d953-9d5f-4441-be71-fe854ba66b15.pdf
View document text
August 13, 2026
To, To,
Dy. General Manager The Manager – Listing,
Department of Corporate Services, National Stock Exchange of India Ltd.,
BSE Ltd., Plot No. C/1, G Block,
P. J. Towers, Dalal Street, Bandra Kurla Complex,
Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051
Ref: Scrip Code: 543322 Ref: Scrip Name: ALIVUS
Dear Sirs,
Sub: Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements)
Regulations, 2015 – Intimation of Investors/Analyst Meetings
With reference to the captioned subject and pursuant to Regulation 30 and Para A of Part A of
Schedule III of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would
like to inform the details of Investors/Analyst meetings to be conducted as follows:
Date Name Mode Place Type of Meeting
August 18, 2026 Green Lantern Capital In-Person Mumbai One on One
August 18, 2026 SIMPL In-Person Mumbai One on One
August 19, 2026 Burman Capital Virtual - One on One
August 19, 2026 Karma Capital In-Person Mumbai One on One
The schedule and mode of meeting may undergo a change due to exigencies on part of the
Investor/Analyst/Company.
You are requested to kindly takes note of the same.
Thanking You,
Your Sincerely,
For Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)
Rudalf Corriea
Company Secretary & Compliance Officer
Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)
Corporate Office: Registered Office:
Technopolis Knowledge Park, A wing, Office No. 401 to 407, Plot No 170-172, Chandramouli Industrial Estate
4th Floor, Mahakali Caves Road, Andheri ( E), Mumbai – 400093 Mohol Bazarpeth, Solapur 413 213, India
T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com